148 related articles for article (PubMed ID: 25200250)
1. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma.
Zhang YS; Chu JH; Cui SX; Song ZY; Qu XJ
Cell Physiol Biochem; 2014; 34(3):903-15. PubMed ID: 25200250
[TBL] [Abstract][Full Text] [Related]
2. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma.
Cui SX; Yu XF; Qu XJ
Cancer Invest; 2016 Oct; 34(9):459-464. PubMed ID: 27673353
[TBL] [Abstract][Full Text] [Related]
3. Des-gamma-carboxyprothrombin: clinical effectiveness and biochemical importance.
Inagaki Y; Tang W; Xu H; Wang F; Nakata M; Sugawara Y; Kokudo N
Biosci Trends; 2008 Apr; 2(2):53-60. PubMed ID: 20103901
[TBL] [Abstract][Full Text] [Related]
4. gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin.
Naraki T; Kohno N; Saito H; Fujimoto Y; Ohhira M; Morita T; Kohgo Y
Biochim Biophys Acta; 2002 Apr; 1586(3):287-98. PubMed ID: 11997080
[TBL] [Abstract][Full Text] [Related]
5. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.
Yue P; Gao ZH; Xue X; Cui SX; Zhao CR; Yuan Y; Yin Z; Inagaki Y; Kokudo N; Tang W; Qu XJ
Eur J Cancer; 2011 May; 47(7):1115-24. PubMed ID: 21349701
[TBL] [Abstract][Full Text] [Related]
6. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Fujikawa T; Shiraha H; Yamamoto K
Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286
[TBL] [Abstract][Full Text] [Related]
7. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue.
Yamagata H; Nakanishi T; Furukawa M; Okuda H; Obata H
J Gastroenterol Hepatol; 1995; 10(1):8-13. PubMed ID: 7620113
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
9. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
11. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Murata K; Sakamoto A
Int J Oncol; 2008 Dec; 33(6):1149-55. PubMed ID: 19020747
[TBL] [Abstract][Full Text] [Related]
12. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ
Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763
[TBL] [Abstract][Full Text] [Related]
13. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells.
Gao FJ; Cui SX; Chen MH; Cheng YN; Sun LR; Ward SG; Kokudo N; Tang W; Qu XJ
Life Sci; 2008 Dec; 83(23-24):815-20. PubMed ID: 18976674
[TBL] [Abstract][Full Text] [Related]
14. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX
Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646
[TBL] [Abstract][Full Text] [Related]
15. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review.
Weitz IC; Liebman HA
Hepatology; 1993 Oct; 18(4):990-7. PubMed ID: 8406374
[TBL] [Abstract][Full Text] [Related]
16. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma.
Tanaka T; Taniguchi T; Sannomiya K; Takenaka H; Tomonari T; Okamoto K; Kitamura S; Okahisa T; Tamaki K; Mikasa H; Suzuki S; Takayama T
J Gastroenterol Hepatol; 2013 Aug; 28(8):1348-55. PubMed ID: 23432345
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Murata K; Suzuki H; Okano H; Oyamada T; Yasuda Y; Sakamoto A
Int J Oncol; 2010 Jan; 36(1):161-70. PubMed ID: 19956845
[TBL] [Abstract][Full Text] [Related]
18. Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K.
Furukawa M; Nakanishi T; Okuda H; Ishida S; Obata H
Cancer; 1992 Jan; 69(1):31-8. PubMed ID: 1309308
[TBL] [Abstract][Full Text] [Related]
19. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.
Suzuki M; Shiraha H; Fujikawa T; Takaoka N; Ueda N; Nakanishi Y; Koike K; Takaki A; Shiratori Y
J Biol Chem; 2005 Feb; 280(8):6409-15. PubMed ID: 15582995
[TBL] [Abstract][Full Text] [Related]
20. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
